The antiviral pill Paxlovid does not significantly reduce COVID-19 hospitalizations in vaccinated older adults, according to ...

Most of us are pretty adept by now at managing COVID-19, with an armor of past infections, vaccinations, self-tests, and antiviral medications like Paxlovid. In the latest study, however ...

Covid hospitalizations were not significantly reduced when adults used the antiviral pill, researchers find. Also, a nationwide study suggests estrogen may play a role in long covid, putting women at ...

Please provide your email address to receive an email when new articles are posted on . Paxlovid may not decrease the risk for hospitalization or death among older adults who are vaccinated.

Follow-up rates were similar in the treated and untreated groups, with slightly more adverse events demonstrated in the Paxlovid vs control group. Researchers conducted a retrospective electronic ...

Paxlovid, one of the most well-known treatments for COVID-19, has also been shown to ease symptoms of some patients with long COVID — and new research suggests the antiviral medication could ...

US biotech Enanta Pharma has filed a lawsuit against Pfizer, claiming that its oral antiviral for COVID-19 Paxlovid infringes one of its patents and seeking damages from the pharma giant.

Among high-risk patients, treatment with paxlovid reduces the COVID-19 burden. Researchers conducted a phase 2/3, double-blind, randomized study (Evaluation of Protease Inhibition for COVID-19 in High ...

A study yesterday in JAMA suggests Paxlovid, the oral antiviral approved for use against severe COVID-19 symptoms, did little to lessen the risk of hospitalizations and death among older, vaccinated ...

It has now been over six months since the FDA authorized Paxlovid in December 2021 “for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older ...